STAT reports on U.S. officials pressuring Germany over drug prices and biotech companies reconsidering clinical trials due to FDA changes.
Over a recent breakfast meeting, U.S. Trade Representative Jamieson Greer, chief health department adviser Chris Klomp, and German Ambassador Jens Hanefeld discussed the issue of pharmaceutical pricing. The discussion was part of a larger push from the Trump administration to get other countries to pay more for medications as the United States pays less, according to STAT. U.S. officials suggested using tariffs under Section 301, which grants the government authority to combat trade practices considered "unfair." While the German ambassador agreed to review the matter with his country's officials, no deal was reached.
Meanwhile, some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States due to concerns about layoffs and policy changes at the FDA under President Trump. Mass layoffs, leadership exits, and restructuring at the agency have prompted smaller biotechs to rethink traditional pathways for bringing new medicines to market. Reuters spoke with seven biotech executives, investors, and consultants who staff departures and policy changes had led some firms to consider launching trials in other international markets such as the European Union and Australia earlier in the drug development process.
The STAT+ Exclusive Story highlights these developments, underscoring the ongoing challenges faced by both pharmaceutical companies and regulatory bodies. As the U.S. continues to pressure Germany on drug prices, biotech companies are also facing significant changes at home that could affect their clinical trial strategies. This shift underscores the complex interplay between global trade policies and domestic regulatory environments in the rapidly evolving pharmaceutical industry.
As we move into another working week, it is clear that the landscape of healthcare innovation remains dynamic and fraught with challenges. Whether through international negotiations or internal organizational shifts, stakeholders are adapting to ensure the continued development and accessibility of new medicines.
